Hyaluronic Acid for Vaginal Dryness

Hyaluronic acid used inside the vagina helps vaginal dryness modestly; hyaluronic acid swallowed as a supplement has no evidence for it at all. A 2026 meta-analysis of 11 randomised trials of hyaluronic acid in postmenopausal women found that in the three placebo-controlled trials hyaluronic acid improved dryness-related quality of life (standardised mean difference -0.98, 95% CI -1.24 to -0.71), rated moderate certainty. In trials against other treatments it was not inferior (Dahab 2026).

Those trials were small, short and used different products, and the comparisons are less flattering than the headline. Vaginal estrogen eased dryness better in a 300-woman trial (P = 0.012) (Jafarzade 2024), and a polycarbophil moisturiser did as well as hyaluronic acid gel (Cagnacci 2022). So the verdict is mixed: a real but moisturiser-sized benefit from the vaginal form, and nothing shown for pills.

Hyaluronic acid is a sugar-based molecule that binds water. Used as a vaginal gel or suppository it acts as a moisturiser: it hydrates and coats the lining rather than changing hormone levels. Systematic reviewers describe it as a vaginal treatment with a moisturizing action, suited to women who can't use estrogen (Buzzaccarini 2021).

That also explains its limits. Estrogen restores the lining more strongly. In an 8-week trial, atrophy and cell maturation improved with both treatments, but maturation improved significantly more with estradiol tablets (P < 0.001) (Ekin 2011), and after estriol cream vaginal pH was lower than after hyaluronic acid gel (Stute 2013).

Oral hyaluronic acid has been tested for skin: 120 mg a day for 12 weeks improved skin moisture and wrinkles in 40 adults (Hsu 2021). That is a different tissue and a different question. No trial has measured whether oral hyaluronic acid changes the vaginal lining or eases dryness. The only oral data come from a 20-woman, non-randomised pilot in which a multi-ingredient supplement, containing collagen peptides, ultra-low-molecular-weight hyaluronic acid and other components, was added to vaginal laser treatment (Tafuri 2025). It can't show what hyaluronic acid alone does.

Every positive trial used hyaluronic acid inside the vagina, and products and schedules varied. One trial used 5 mg hyaluronic acid vaginal tablets for 8 weeks (Ekin 2011); another a gel every 3 days for 10 applications over 30 days (Chen 2013); another suppositories three times a week for 3 months (Gold 2023). In cancer survivors, a gel used daily for 2 weeks and then three times a week helped; the investigators noted that 1-2 applications a week are recommended in natural menopause, and that 3-5 a week appear more effective in cancer survivors (Carter 2021).

No oral hyaluronic acid dose has been shown to ease vaginal dryness, so there is no supplement dose to recommend for it. Some vaginal products also combine hyaluronic acid with other ingredients, such as a gel with sea buckthorn oil, aloe vera and glycogen tested against placebo (De Seta 2021), so results from one product don't automatically apply to another.

For mild symptoms, the North American Menopause Society says non-prescription moisturisers and lubricants give enough relief for most women, and lists low-dose vaginal estrogen, vaginal DHEA, systemic estrogen and ospemifene as effective for moderate to severe symptoms (NAMS 2020).

The 2026 meta-analysis included 11 randomised trials in postmenopausal women. In its three placebo-controlled trials, hyaluronic acid improved dryness-related quality of life (SMD -0.98), sexual function on the Female Sexual Function Index (SMD 0.85, 95% CI 0.50 to 1.20) and the Vaginal Health Index (SMD 3.40). GRADE certainty was moderate for dryness and sexual function but low for the Vaginal Health Index and safety, and the authors called for more standardised formulations and longer studies (Dahab 2026).

One small placebo trial shows why caution matters. In 36 postmenopausal women, a daily high-molecular-weight hyaluronic acid gel and a placebo gel both reduced dryness significantly; only hyaluronic acid reduced itching (P < 0.02) and burning (P < 0.04) (Grimaldi 2012). Any gel adds moisture, so some of the benefit may come from that.

Earlier reviews concluded hyaluronic acid performs about as well as vaginal estrogen. A 2021 review of 5 trials in 335 women found no significant difference for atrophy, pH, painful sex or cell maturation, but couldn't pool the results (Dos Santos 2021). The trials themselves point both ways:

In 144 women, dryness improved in 84.44% after 30 days of hyaluronic acid gel and 89.42% with estriol cream, a non-significant difference (Chen 2013). In a 12-week pilot of 45 women, symptom scores did not differ from estrogen cream (P = 0.81) (Agrawal 2024). But estradiol tablets relieved symptoms better than 5 mg hyaluronic acid tablets in 42 women (P < 0.05) (Ekin 2011), and in 300 women estrogen eased dryness better after a month (P = 0.012), while hyaluronic acid eased itching better (P = 0.002) (Jafarzade 2024). One 56-woman trial found hyaluronic acid better for dryness (P < 0.05) (Jokar 2016). Most of these trials were open-label or didn't report blinding.

Hyaluronic acid hasn't clearly beaten simpler products. In 53 women in the menopausal transition, a polycarbophil moisturiser twice a week was non-inferior to hyaluronic acid gel over 30 days, and the authors concluded hyaluronic acid gel gave no additional benefit (Cagnacci 2022). In 80 postmenopausal women, the share whose dryness improved did not differ between a hyaluronic acid gel and a water-based lubricant over 3 months; only a sensitivity analysis of the dryness score favoured hyaluronic acid (Nappi 2022).

Independent reviews put it in the same category. A review for the US Agency for Healthcare Research and Quality found vaginal moisturisers in general may improve dryness, with low certainty (Danan 2024), and a review for the Society of Gynecologic Surgeons found hyaluronic acid improved subjective and objective signs of atrophy but there are insufficient data to compare non-estrogen options with each other (Casiano Evans 2023).

In 43 breast cancer survivors, hyaluronic acid suppositories three times a week improved the Vaginal Health Index as much as vaginal laser over 3 months (P = 0.232 between groups) (Gold 2023). In an uncontrolled study of 101 survivors of hormone receptor-positive breast or endometrial cancer, symptom scores improved at every visit up to 22-24 weeks (P < 0.001) (Carter 2021).

What's missing: any trial of oral hyaluronic acid for vaginal dryness, large blinded placebo-controlled trials, and data beyond about 6 months. Injected cross-linked hyaluronic acid, a clinic procedure, eased dryness more than placebo over 12 weeks in 116 women (-0.87, 95% CI -1.27 to -0.47) (Marchand Lamiraud 2025), but that is a different treatment from gels or supplements. For a prescription comparison, see DHEA for vaginal dryness; for oral hyaluronic acid's own evidence, see hyaluronic acid for skin hydration.

Vaginal hyaluronic acid was well tolerated. The 2026 meta-analysis found no serious adverse events and few treatment discontinuations (Dahab 2026), and the pilot comparison with estrogen recorded no treatment-related serious adverse events (Agrawal 2024). In the 144-woman estriol comparison, side effects thought to be related were minor and included vaginal infection and genital itching (Stute 2013).

It contains no hormones, which is why trials have tested it in women after breast cancer (Gold 2023; Carter 2021). The trials enrolled women around or after menopause; pregnant and breastfeeding women were excluded from at least one (Stute 2013), so there are no data for those groups. Oral hyaluronic acid's safety is covered on the hyaluronic acid page; for vaginal dryness it has no proven benefit to weigh against any risk.

No drug interactions are known for vaginal hyaluronic acid. The practical questions are about combining it with other vaginal treatments, which trials compared rather than combined (Chen 2013; Agrawal 2024).